Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
767.13 K
Value Traded
8.77 M
Short % Float
14.84%
Days to Cover
6.3
-51.7%Week
-46.75%1 Month
-67.07%3 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
275.24 M
EPS (TTM)
-8.18
P/E Ratio
-
Ent. Value
100.44 M
Total Shares
25.84 M
Float Shares
18.40 M
Insiders
28.82%
Institutions
51.95%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
FTH Catalyst Timeline
Dated clinical, regulatory and corporate events for Faeth Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Faeth Therapeutics, Inc.
182Total events
8Upcoming
36Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Faeth management to participate in Guggenheim 3rd Annual Healthcare Innovation Conference (1x1 investor meetings)
▲Topline ReadoutPIKTORClinical Data
Faeth reports positive preliminary Phase 2 topline results for PIKTOR plus paclitaxel in advanced endometrial cancer
advanced endometrioid endometrial cancersource ↗
●R&D DayPIKTORPresentation
Faeth hosts webcast to discuss PIK-201 topline data
advanced endometrioid endometrial cancersource ↗
▲Primary Endpoint MetPIKTORClinical Data
PIKTOR plus paclitaxel achieved 33% confirmed ORR in efficacy-evaluable patients
advanced endometrioid endometrial cancersource ↗
▲Safety Data UpdatePIKTORClinical Data
PIKTOR plus paclitaxel generally well tolerated with 5% treatment-related discontinuation rate
advanced endometrioid endometrial cancersource ↗
●Quarterly UpdateCorporate
Reported third quarter 2026 financial results for quarter ended September 30, 2026
●Poster PresentationPIKTORPresentation
Preclinical PIKTOR data presented in ESMO 2026 poster, including head-to-head vs gedatolisib
HR+/HER2- breast cancersource ↗
▲Fast Track DesignationPIKTORDesignation
FDA granted Fast Track designation to PIKTOR plus paclitaxel
advanced or recurrent endometrial cancer with PI3K/AKT/mTOR pathway alterationsource ↗
◆Poster PresentationPIKTORPresentation
Poster presentation of PK/PD modeling at STOP Cancer conference
second-line advanced endometrial cancersource ↗
●Timing GuidancePresentation
Company name change to Faeth Therapeutics and ticker change to FTH
◆Timing GuidancePresentation
Stockholder vote scheduled for conversion of Series B Preferred Stock
▲Corporate ApprovalCorporate
Stockholders approved conversion of Series B preferred stock into common stock
●Management ChangeCorporate
Anand Parikh appointed Chairman, President and CEO; Brian Stephenson appointed CFO; board strengthened with Stephen M. Hahn and Saira Ramasastry
▲First Patient DosedPIKTORTrial
First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer
HR+/HER2- advanced breast cancersource ↗
▲First Patient DosedPIKTORTrial
First patient dosed in Phase 1b/2 FTH-PIK-101 trial of PIKTOR in HR+/HER2- advanced breast cancer
HR+/HER2- advanced breast cancersource ↗
●Oral PresentationPresentation
Conference call and webcast to discuss acquisition and financing
▼Equity OfferingCorporate
Private placement closed concurrently with acquisition of Faeth, raising ~$200M gross proceeds
●Trial InitiationsolnerstotugTrial
Planned initiation of Phase 2 study for solnerstotug
PD-(L)1 resistant tumorssource ↗
▲Fast Track DesignationPIKTORDesignation
FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer
advanced or recurrent endometrial cancer with PAM pathway alterationsource ↗
▼Program DiscontinuationsolnerstotugCorporate
Discontinuation of solnerstotug development
cancersource ↗
▼Trial DiscontinuedsolnerstotugTrial
Orderly wind-down of ongoing Phase 1/2 clinical trial
cancersource ↗
◆Oral PresentationsolnerstotugPresentation
Mini oral session at ESMO Congress 2025 presenting Phase 1/2 dose expansion results for solnerstotug
PD-(L)1 resistant tumorssource ↗
▲Topline ReadoutsolnerstotugClinical Data
Phase 1/2 dose expansion topline results: 6-month PFS 50% at 15 mg/kg in PD-(L)1 resistant patients
PD-(L)1 resistant tumorssource ↗
▲Runway Guidance UpdateCorporate
Cash runway into Q4 2025, funding midway into Phase 2 studies of SNS-101
▲Enrollment CompletesolnerstotugTrial
Dose expansion enrollment complete
advanced solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How FTH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-09 | PIKTOR (PIK-201) | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 63%
Micro Cap(rank 421 of 667)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Serabelisib Small MoleculesNCT07558733 | HR+ HER2- Breast Cancer | Phase 1/2 | RECRUITING | 32 | May 1, 2033 | ||||||
| Sapanisertib Small MoleculesNCT06463028 | Endometrial Cancer | Phase 2 | RECRUITING | 40 | Sep 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every FTH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| solnerstotug | PD-(L)1 resistant tumors | Phase 1/2 | 2025-10-17 | 6 month PFS at 15 mg/kg: 50%; 6 month PFS at 3 mg/kg: 24%; overall 6 month PFS among 'hot tumor' patients: 37%; clinical responses at 15 mg/kg: 6; clinical responses in PD (L)1 resistant tumors: 5Read More | Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 - 6-month progression-free survival (PFS) of Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| STEPHENSON BRIAN COfficer (Chief Financial Officer) | Buy | 4,400 46,088 held | $23.40 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FTH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 0.3 % | 36.10 M | 1.44 M |
Ownership Trends
FTH Short Interest
Shares sold short, counted twice a month.
14.84%
Short % of Float
of tradable shares sold short
2.7M
Shares Sold Short
+17.7% vs prior count
6.3 High
Days to Cover
trading days of normal volume to buy every short share back
432.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FTH ranks across every disease it competes in
Competitive Position is a premium feature
See how FTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFTH News
-FTH
Nov 11, 2026▼ -20.2%today
Faeth Therapeutics to Participate in Upcoming November Investor Conferences
Faeth Therapeutics announced its participation in two upcoming investor conferences. The company will hold 1x1 meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference and present at the Jefferies Global Healthcare Conference in London. Live webcasts of these events will be accessible on their website.
Read more →-FTH
Nov 9, 2026▼ -42.5%on this newsshared move
Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer
Faeth Therapeutics reported positive topline results from its Phase 2 trial of PIKTOR combined with paclitaxel for advanced endometrial cancer. The confirmed objective response rate was 33%, with a median progression-free survival of 7.4 months. The treatment was generally well tolerated, leading to plans for a Phase 3 trial.
Read more →-FTH
Nov 6, 2026▼ -42.5%on this newsshared move
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
Faeth Therapeutics will host a virtual event on November 9, 2026, to discuss topline results from its Phase 2 PIK-201 trial for advanced endometrial cancer. The event will include insights from principal investigator David Starks and company management. PIKTOR, the investigational therapy, combines serabelisib and sapanisertib to target the PI3K/AKT/mTOR pathway.
Read more →-FTH
Nov 5, 2026▲ +10.7%on this news· ran to -36% by day 1shared move
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics announced the granting of options to three new employees, totaling 68,000 shares. The options, effective November 4, 2026, serve as an inducement under Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $19.99 per share, aligning with the stock's closing price on the grant date.
Read more →-FTH
Nov 3, 2026Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
Faeth Therapeutics reported its Q3 2026 financial results, highlighting the FDA's Fast Track designation for PIKTOR in advanced endometrial cancer. The company anticipates topline results from its Phase 2 PIK-201 trial by year-end. Financially, Faeth experienced a net loss of $20.4 million, up from $4.6 million in the same quarter last year.
Read more →-FTH
Oct 27, 2026▲ +13.5%on this news
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Faeth Therapeutics appointed Dr. Adam Schayowitz to its Board of Directors. Dr. Schayowitz has nearly 20 years of experience in oncology drug development, having led numerous global programs. He will contribute to the advancement of Faeth's lead program, PIKTOR, in clinical trials for endometrial and breast cancer.
Read more →-FTH
Oct 23, 2026▼ -15%on this newsshared move
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
Faeth Therapeutics presented promising preclinical data for PIKTOR at ESMO 2026, showing it inhibited tumor growth in breast cancer models effectively. PIKTOR outperformed gedatolisib and achieved complete tumor growth inhibition when combined with fulvestrant and palbociclib. The findings support ongoing trials, with interim data expected in 2027.
Read more →-FTH
Oct 19, 2026Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
Faeth Therapeutics will present preclinical data on its investigational therapy PIKTOR at the ESMO Congress 2026. The data will showcase PIKTOR's efficacy as a monotherapy and in combination with other treatments for HR+/HER2- breast cancer. This presentation aims to inform the ongoing FTH-PIK-101 trial, with results from mouse models and cellular assays included.
Read more →-FTH
Sep 17, 2026Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
Faeth Therapeutics has appointed Dr. Karen Vousden to its Board of Directors, effective September 11, 2026. Dr. Vousden has been instrumental in shaping the company's scientific direction and has served as a trusted advisor since its founding. Her expertise is expected to enhance the company's strategic initiatives in cancer treatment.
Read more →-FTH
Sep 8, 2026Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
Faeth Therapeutics has announced a virtual key opinion leader event scheduled for October 6, 2026. The event will feature Dr. Marcus Goncalves from NYU Langone Health, who will discuss the PAM pathway in relation to endometrial cancer. This initiative highlights the company's commitment to advancing cancer treatment through expert collaboration.
Read more →-FTH
Sep 1, 2026▲ +5.3%on this news· ran to +22% by day 3
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
Faeth Therapeutics, a clinical-stage oncology company, has announced its participation in two upcoming investor conferences. The events include the Wells Fargo 21st Annual Healthcare Conference and the Citi Biopharma Back to School Summit. This engagement aims to showcase their lead program, PIKTOR, and connect with potential investors.
Read more →-FTH
Aug 17, 2026Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
Faeth Therapeutics has received Fast Track designation from the FDA for its PIKTOR combination therapy, which includes sapanisertib and serabelisib with paclitaxel. This designation is specifically for treating patients with advanced or recurrent endometrial cancer that have specific genetic alterations. The Fast Track status aims to expedite the development and review process for this promising treatment.
Read more →-FTH
Aug 14, 2026▲ +13.3%on this newsshared move
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
Faeth Therapeutics has announced the appointment of Deepak Tiwari as Senior Vice President of Technical Operations and Matt Biegler as Senior Vice President of Investor Relations. These appointments are part of the company's strategy to strengthen its leadership team in preparation for upcoming clinical milestones related to its PIKTOR program.
Read more →-FTH
Aug 7, 2026Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
Faeth Therapeutics will present important PK/PD modeling data for its investigational drug PIKTOR at the upcoming STOP Cancer conference. This data will inform the dose selection for the ongoing FTH-PIK-201 trial. The conference is scheduled for August 7-8, 2026, in New York, highlighting the company's commitment to oncology research.
Read more →-FTH
Aug 4, 2026▼ -6.7%on this newsshared move
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
Faeth Therapeutics announced its financial results for the second quarter of 2026, showcasing key corporate achievements and future milestones. The CEO, Anand Parikh, emphasized the significance of their recent collaboration with Sensei Biotherapeutics. This partnership is viewed as a pivotal moment for the company's growth and development in oncology.
Read more →About Faeth Therapeutics, Inc.
Headquarters701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702
BIOPHARMAWATCH ELITE
Trade the next FTH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime